Related to heart failure, a phase 1B trial with the specific NLRP3 inhibitor dapansutrile (OLT1177) has been completed in patients with stable systolic heart failure (https://clinicaltrials.gov/ct2/show/NCT03534297, accessed October 2021). The gene discussed is NLRP3; the disease is heart failure.